TipRanks
Champions Oncology Inc (DE:2I3)
FRANKFURT:2I3

Champions Oncology (2I3) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Champions Oncology has a market cap or net worth of €59.38M. The enterprise value is €81.67.
Market Cap€59.38M
Enterprise Value€81.67

Share Statistics

Champions Oncology has 13,918,569 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,918,569
Owned by Insiders14.79%
Owned by Institutions32.88%

Financial Efficiency

Champions Oncology’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -13.28%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-13.28%
Return on Capital Employed (ROCE)-0.16
Revenue Per Employee277.69K
Profits Per Employee-5.49K
Employee Count214
Asset Turnover2.20
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Champions Oncology is ―. Champions Oncology’s PEG ratio is 0.60.
PE Ratio
PS Ratio1.39
PB Ratio20.93
Price to Fair Value20.93
Price to FCF-16.37
Price to Operating Cash Flow-11.91
PEG Ratio0.60

Income Statement

In the last 12 months, Champions Oncology had revenue of 59.42M and earned -1.18M in profits. Earnings per share was -0.08.
Revenue59.42M
Gross Profit28.52M
Operating Income-1.14M
Pretax Income-929.00K
Net Income-1.18M
EBITDA448.00K
Earnings Per Share (EPS)-0.08

Cash Flow

In the last 12 months, operating cash flow was -5.56M and capital expenditures -573.00K, giving a free cash flow of -6.14M billion.
Operating Cash Flow-5.56M
Free Cash Flow-6.14M
Free Cash Flow per Share-0.44

Dividends & Yields

Champions Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.58
52-Week Price Change-36.79%
50-Day Moving Average4.54
200-Day Moving Average5.03
Relative Strength Index (RSI)41.76
Average Volume (3m)0.00

Important Dates

Champions Oncology upcoming earnings date is Dec 15, 2026, After Close (Confirmed).
Last Earnings DateSep 10, 2026
Next Earnings DateDec 15, 2026
Ex-Dividend Date

Financial Position

Champions Oncology as a current ratio of 0.96, with Debt / Equity ratio of 281.79%
Current Ratio0.96
Quick Ratio0.96
Debt to Market Cap0.00
Net Debt to EBITDA-0.80
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Champions Oncology has paid 246.00K in taxes.
Income Tax246.00K
Effective Tax Rate-0.26

Enterprise Valuation

Champions Oncology EV to EBITDA ratio is 183.22, with an EV/FCF ratio of -16.30.
EV to Sales1.38
EV to EBITDA183.22
EV to Free Cash Flow-16.30
EV to Operating Cash Flow-18.35

Balance Sheet

Champions Oncology has €4.36M in cash and marketable securities with €10.97M in debt, giving a net cash position of -€6.61M billion.
Cash & Marketable Securities€4.36M
Total Debt€10.97M
Net Cash-€6.61M
Net Cash Per Share-€0.48
Tangible Book Value Per Share€0.27

Margins

Gross margin is 49.30%, with operating margin of -1.92%, and net profit margin of -1.98%.
Gross Margin49.30%
Operating Margin-1.92%
Pretax Margin-1.56%
Net Profit Margin-1.98%
EBITDA Margin0.75%
EBIT Margin-1.56%

Analyst Forecast

The average price target for Champions Oncology is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-0.02%
EPS Growth Forecast-132.40%

Scores

Smart Score2
AI Score